Tumor hypoxia: The major culprit behind cisplatin resistance in cancer patients.
Saved in:
| Title: | Tumor hypoxia: The major culprit behind cisplatin resistance in cancer patients. |
|---|---|
| Authors: | Devarajan N; Central Research Laboratory, Meenakshi Ammal Dental College, Meenakshi Academy of Higher Education and Research, Maduravoyal, Chennai, 600095, Tamilnadu, India. Electronic address: drnalini.crl@madch.edu.in., Manjunathan R; Multidisciplinary Research Unit, Chengalpattu Government Medical College, Chengalpattu, 603001, Tamilnadu, India. Electronic address: rejimanjunath@gmail.com., Ganesan SK; Laboratory of Functional Genomics, Structural Biology & Bioinformatics Division, CSIR-Indian Institute of Chemical Biology, TRUE Campus, CN Block-6, Sector V, Salt Lake, Kolkata, 700 091, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. Electronic address: skumar@iicb.res.in. |
| Source: | Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2021 Jun; Vol. 162, pp. 103327. Date of Electronic Publication: 2021 Apr 20. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
